<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01035580</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00020139</org_study_id>
    <nct_id>NCT01035580</nct_id>
  </id_info>
  <brief_title>Trial on Safety and Pharmacokinetics of Intravaginal Curcumin</brief_title>
  <official_title>Phase I Trial on Safety and Pharmacokinetics of Intravaginal Curcumin in Normal Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to determine the maximum tolerable dose and safety of&#xD;
      intravaginal curcumin in a normal population of women (women with no evidence of cervical&#xD;
      cytological abnormalities by pap testing).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is to reach the maximum selected dose (MSD) or maximum tolerated dose (MTD) of intravaginal curcumin among Pap test negative women without causing a dose-limiting toxicity.</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Uterine Cervical Dysplasia</condition>
  <arm_group>
    <arm_group_label>curcurim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This was a 3 + 3 dose escalation trial starting at 500 mg of cur cumin capsules administered daily intravaginally for 14 days. The dose increased after safety was demonstrated in 3 subjects by 500 mg up to a max of 2000 mgs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Curcumin 500 mg capsules will be inserted intravaginally once daily for 14 days for a maximum daily dosage of 2000 mg</description>
    <arm_group_label>curcurim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>curcumin</intervention_name>
    <description>all patients received the drug</description>
    <arm_group_label>curcurim</arm_group_label>
    <other_name>Sabinsa Curcumin Capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between the ages of 18-45 years of age at enrollment&#xD;
&#xD;
          -  Currently using a reliable birth control method (oral contraceptive pills, DepoProvera&#xD;
             or permanent sterilization)&#xD;
&#xD;
          -  Able to provide written informed consent&#xD;
&#xD;
          -  Provide male partner notification letter&#xD;
&#xD;
          -  Have a Pap test negative pap (no cervical intraepithelial lesions) within 45 days&#xD;
             prior to screening&#xD;
&#xD;
          -  Have regular monthly menses (every 21-35 days) or amenorrhea due to hormonal&#xD;
             contraceptive use&#xD;
&#xD;
          -  Agree to undergo pelvic exam and colposcopy per protocol&#xD;
&#xD;
          -  Able and willing to complete Study Diary&#xD;
&#xD;
          -  Agree to wear condoms during all acts of vaginal intercourse or abstain from vaginal&#xD;
             intercourse during the 14 days&#xD;
&#xD;
          -  Agree to abstain from sexual intercourse for 48 hours prior to the enrollment visit&#xD;
&#xD;
          -  Agree to insert curcumin gelatin capsules as required per protocol&#xD;
&#xD;
          -  Agree to abstain from nonsteroidal anti-inflammatory drugs (NSAIDS) during the 14 days&#xD;
&#xD;
          -  Agree to abstain from all products containing curcumin or food consumption of curcumin&#xD;
             during the 14 days&#xD;
&#xD;
          -  Agree to abstain from the following activities for at least 48 hours prior to&#xD;
             enrollment through the Day 14 visit:insertion of objects into the vagina except for a&#xD;
             penis, receiving oral or anal sex,using a diaphragm, cervical cap, female condom, or&#xD;
             vaginal contraceptive ring,using vaginal products other than the study gelatin&#xD;
             capsules, including douches, lubricants, spermicide or feminine hygiene&#xD;
             products,participating in other vaginal cream or contraceptive studies&#xD;
&#xD;
          -  Agree to testing for HIV status via enzyme immunoassay (EIA)/Western Blot&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are post-menopausal&#xD;
&#xD;
          -  Have had a hysterectomy with removal of the cervix&#xD;
&#xD;
          -  Have a clinically significant chronic medical condition that is considered&#xD;
             progressive, including: coronary disease, congestive heart failure, chronic&#xD;
             obstructive lung disease, diabetes mellitus, chronic renal disease, active peptic&#xD;
             ulcer disease, chronic hepatic disease, multiple sclerosis, seizure disorder requiring&#xD;
             medication, and a coagulation or platelet disorder. Chronic nonprogressive or&#xD;
             intermittent syndromes are not excluded, including migraine headaches, mild reactive&#xD;
             airways disease, controlled hypertension, stable pain syndromes, or benign gastric&#xD;
             reflux.&#xD;
&#xD;
          -  Have an intrauterine device (IUD) as a form of birth control&#xD;
&#xD;
          -  Have any history of malignancy or current (within 45 days of screening) pap with&#xD;
             cervical intraepithelial lesions.&#xD;
&#xD;
          -  Currently has documented lacerations on visual inspection present on the cervix,&#xD;
             vagina, vulva or perineum.&#xD;
&#xD;
          -  Are pregnant or planning to become pregnant in the next three months&#xD;
&#xD;
          -  Are currently breastfeeding&#xD;
&#xD;
          -  Have a history of sensitivity or allergy to any compound used in this study&#xD;
&#xD;
          -  Have Grade 2 or higher renal or hematologic abnormality, as defined by the Table for&#xD;
             Grading the Severity of Adult Adverse Events or at screening have a positive bacterial&#xD;
             urine culture. Women with a positive bacterial urine culture at screening will be&#xD;
             allowed to enroll after appropriate treatment if repeat evaluation is normal.&#xD;
&#xD;
          -  In the three months prior to enrollment have had any of the following:Treatment for&#xD;
             Cervical disease or any other gynecologic surgery,A pregnancy or an abortion, An&#xD;
             IUD,Breakthrough menstrual bleeding or vaginal bleeding during or following vaginal&#xD;
             intercourse&#xD;
&#xD;
          -  Signs, as seen on pelvic exam at screening, consistent with an STD including&#xD;
             vaginitis, cervicitis or genital ulcers&#xD;
&#xD;
          -  Signs, as seen on pelvic exam, of genital trauma&#xD;
&#xD;
          -  Signs of genital tract infection from laboratory evaluations. Women with Candida&#xD;
             vaginitis or bacterial vaginosis at screening will be allowed to enroll after&#xD;
             appropriate treatment and if repeat evaluation is normal.&#xD;
&#xD;
          -  In the three months prior to enrollment have had any of the following:History of&#xD;
             treatment for or a diagnosis with a new STD,Genital herpes simplex virus infection or&#xD;
             outbreak,Exchanged sex for money, drugs or gifts&#xD;
&#xD;
          -  Are currently using, or in the last year have used intravenous drugs (except for&#xD;
             therapeutic use), cocaine or other recreational drugs, abused alcohol defined as&#xD;
             alcohol use that has required hospital admission for detoxification and therapy.&#xD;
&#xD;
          -  Have any other condition that in the opinion of the investigator might interfere with&#xD;
             the evaluation of the study objectives.&#xD;
&#xD;
          -  HIV positive&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Flowers, Medical</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>December 17, 2009</study_first_submitted>
  <study_first_submitted_qc>December 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2009</study_first_posted>
  <last_update_submitted>November 27, 2013</last_update_submitted>
  <last_update_submitted_qc>November 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Lisa Flowers</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>chemoprevention</keyword>
  <keyword>curcumin</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

